Company: OSRH
Filing Date: 2025-04-22
Form Type: 10-K
Source: 0001213900-25-034116
Chunk: 338

Company: OSR Holdings, Inc.
Filing Date: 2025-04-22
Form: 10-K
Item: Item 1A
Chunk 338
---
 not yet known. We cannot predict how CMS will interpret the
IRA or how the provisions of the law will affect our business once fully implemented.

52

At the state level, legislatures are increasingly passing legislation
and implementing regulations designed to control pharmaceutical and biologic product pricing, including price or patient reimbursement
constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, requirements for
substitution of generic products, and, in some cases, designed to encourage importation from other countries and bulk purchasing.

These laws, and future state and federal healthcare reform measures
that may be adopted in the future, could adversely affect the prices we may obtain for any of our product candidates or the frequency
with which any such product candidate is prescribed or used. We expect to experience pricing pressures in connection with the sale of
any future approved product candidates due to the trend toward managed healthcare, the increasing influence of health maintenance organizations,
cost containment initiatives and additional legislative changes, all of which may adversely affect our business and future profits.

If the Company’s officers and directors serve as directors
or officers of majority-owned subsidiaries, those individuals will have fiduciary and other duties to those subsidiaries and
their minority stockholders, potentially causing conflicts of interest between their duties to the Company and their duties to those subsidiaries.

Certain of our directors or officers, including Mr. Hwang, are
also directors and/or officers of one or more of our subsidiaries and, if those subsidiaries were to become majority-owned subsidiaries
(as a result of third-party financing or investments), our officers would have fiduciary or other duties both to us and any majority-owned subsidiaries
(including future subsidiaries). The conflicts of interest that arise from such duties could interfere with the management of those subsidiaries
and their programs and product candidates, or result in disagreements with our majority-owned subsidiaries’ other stockholders.
For example, an individual who is both our director and a director of one of our subsidiaries, owes fiduciary duties to the subsidiary
and to us, and such individual may encounter circumstances in which his or her decision or action may benefit the subsidiary while having
a detrimental impact on us, or vice versa, or on another subsidiary. Further, our officers and directors who are also officers and directors
of any majority-owned subsidiaries will need to allocate his or her time to responsibilities owed to us and each of the subsidiaries
for which he or she serves as an officer or